Moleculin Biotech
MBRX
MBRX
22 hedge funds and large institutions have $2.91M invested in Moleculin Biotech in 2023 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
33% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 6
Holders
22
Holding in Top 10
–
Calls
–
Puts
–
Top Buyers
| 1 | +$23K | |
| 2 | +$15K | |
| 3 | +$14.8K | |
| 4 |
TSS
Two Sigma Securities
New York
|
+$13K |
| 5 |
Renaissance Technologies
New York
|
+$11.9K |
Top Sellers
| 1 | -$38.8K | |
| 2 | -$24.9K | |
| 3 | -$11.9K | |
| 4 |
Rockefeller Capital Management
New York
|
-$1K |
| 5 |
CA
Clearstead Advisors
Cleveland,
Ohio
|
-$636 |